Altos Labs

What it is

Altos Labs is a privately held biotech launched in January 2022 with ~$3B in initial funding from Yuri Milner, Jeff Bezos, and others. It operates research institutes in Cambridge (UK), San Diego, and the San Francisco Bay Area, plus collaboration with several universities.

Focus

• Cellular health and rejuvenation through partial Yamanaka-factor reprogramming.
• Mechanistic understanding of how rejuvenation works and how to deliver it safely.
• Foundational science, with an explicit long time horizon.

Notable hires

Altos has attracted senior scientists including Shinya Yamanaka, Steve Horvath, Manuel Serrano, Juan Carlos Izpisua Belmonte, Wolf Reik, Morgan Levine, and Jennifer Doudna (advisor). The talent concentration is unusual for a single private company.

State of progress

Altos remains pre-clinical / very-early-translational; no products or clinical-stage candidates have been disclosed publicly as of writing. The company is explicitly framed around long timescales (a decade+ to products).

Why it matters

Altos is a useful signal of where serious biotech capital believes the rejuvenation field can go. Whatever the eventual products, the basic- science publications coming from Altos labs will shape the partial- reprogramming agenda.

Related entries

Partial reprogramming, Information theory of aging, Steve Horvath, Morgan Levine.